- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04077762
Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH) (REBIRTH)
June 27, 2022 updated by: Minneapolis Heart Institute Foundation
Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access SIte Complication Reduction in Cardiac Catheterization (REBIRTH)
This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization.
Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access.
Randomization will be performed in blocks of 50 per site.
Similarly, a second sub-randomization will be performed in the femoral access group into use of 18 vs 21 gauge needles, also in a 1:1 fashion.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
3266
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bavana Rangan, BDS, MPH, CCRP
- Phone Number: 612-863-3852
- Email: bavana.rangan@allina.com
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Recruiting
- Minneapolis Heart Institute Foundation
-
Contact:
- Bavana Rangan, BDS, MPH, CCRP
- Phone Number: 612-863-3852
- Email: bavana.rangan@allina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 years and older
- Undergoing diagnostic angiography for ischemic symptoms with possible PCI, or undergoing planned urgent or elective PCI
- Has provided informed consent and agrees to participate
- Patients must be equally eligible to undergo cardiac catheterization via radial or femoral access
Exclusion Criteria:
- Primary PCI for STEMI
- Planned right heart catheterization
- Valvular heart disease requiring valve surgery within 30 days after the index procedure
- Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (the opposite arm may be used for radial access if a dialysis graft is present in one)
- Peripheral arterial disease prohibiting vascular access
- Presence of bilateral internal mammary artery coronary bypass grafts
- International normalized ratio ≥1.5 while treated with oral vitamin K antagonists (i.e. warfarin) Receipt of oral factor Xa or IIa inhibitors ≤24 h before procedure
- Planned staged PCI within 30 days after index procedure.
- Any planned surgeries within 30 days after index procedure
- Planned dual arterial access (for example for chronic total occlusion PCI)
- Coexisting conditions that limit life expectancy to less than 30 days
- Positive pregnancy test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Radial access
Radial access for cardiac catheterization.
Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
|
Radial Access
|
ACTIVE_COMPARATOR: State-of-the-art femoral access
Femoral access for cardiac catheterization.
Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
|
State-of-the-art femoral access with 18 gauge needle
State-of-the-art femoral access with 21 gauge needle.
For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of the composite of vascular access complications and bleeding (BARC 2, 3, or 5)
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of BARC type 2, 3, or 5 bleeding events
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Number of Vascular access complications defined as the composite of arteriovenous fistula, arterial pseudoaneurysm, or arterial occlusion requiring intervention;
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Number of participants with Radial artery occlusion
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Number of participants with Access site crossover
Time Frame: Measured during procedure
|
The inability to complete the procedure from the assigned arterial access site, requiring conversion from radial to femoral access or vice versa for procedure completion
|
Measured during procedure
|
Number of other vascular access related complications
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Total procedure time
Time Frame: Measured during procedure
|
The time from administration of local anesthesia to the time of removal of all interventional equipment
|
Measured during procedure
|
Time to ambulation
Time Frame: Measured up to 24 hours after procedure completion
|
Measured up to 24 hours after procedure completion
|
|
Number of all cause death and cardiac death
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Number of participants with Myocardial Infarction
Time Frame: Evaluations will occur up to 30 days
|
The 4th Universal Definition of myocardial infarction
|
Evaluations will occur up to 30 days
|
Number of participants with Stroke
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Number of participants with unplanned coronary revascularization
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Measure of Radiation Dose
Time Frame: Measured during procedure
|
Both air kerma and dose air product
|
Measured during procedure
|
Fluoroscopy Time
Time Frame: Measured during procedure
|
Measured during procedure
|
|
Contrast volume
Time Frame: Measured during procedure
|
Measured during procedure
|
|
Number of participants with Procedural Success
Time Frame: Evaluations will occur up to 30 days
|
Using the National Cardiovascular Disease Registry (NCDR) definition
|
Evaluations will occur up to 30 days
|
Duration of hospital stay and frequency of same day discharge
Time Frame: Evaluations will occur up to 30 days
|
Evaluations will occur up to 30 days
|
|
Patient Preference Survey: Radial Vs Femoral Access
Time Frame: Evaluations will occur up to 30 days
|
Participants will be asked which access site they would have preferred to have their procedure
|
Evaluations will occur up to 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Emmanouil Brilakis, MD, PhD, Minneapolis Heart Institute Foundation
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 15, 2019
Primary Completion (ANTICIPATED)
August 19, 2023
Study Completion (ANTICIPATED)
August 19, 2024
Study Registration Dates
First Submitted
August 26, 2019
First Submitted That Met QC Criteria
September 3, 2019
First Posted (ACTUAL)
September 4, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 28, 2022
Last Update Submitted That Met QC Criteria
June 27, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REBIRTH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patient Satisfaction
-
Shaukat Khanum Memorial Cancer Hospital & Research...Enrolling by invitationSatisfaction, Patient | SatisfactionPakistan
-
Cedars-Sinai Medical CenterTerminated
-
Universitair Ziekenhuis BrusselUnknownPatient Satisfaction | Patient PreferenceBelgium
-
HaEmek Medical Center, IsraelUnknownPatient Satisfaction | Patient Compliance
-
Acibadem UniversityCompletedPatient Satisfaction | Patient Relations, NurseTurkey
-
Samsun UniversityRecruiting
-
University of UtahActive, not recruitingPatient SatisfactionUnited States
-
Fatma mahannaCompleted
-
Medical University of ViennaCompletedPatient SatisfactionAustria
-
Ziekenhuis Oost-LimburgCompleted
Clinical Trials on Radial Access
-
Yonsei UniversityCompleted
-
Wujin People's HospitalCompletedCoronary Artery Disease | Radial Artery Occlusion | Distal Radial ArteryChina
-
Huashan HospitalNot yet recruiting
-
Acibadem UniversityCompleted
-
Carilion ClinicTerminatedAortic Stenosis | Aortic Valve Disease | Vascular Access ComplicationUnited States
-
Instituto Mexicano del Seguro SocialEnrolling by invitationCoronary Artery DiseaseMexico
-
North Texas Veterans Healthcare SystemCompletedVascular Access ComplicationUnited States
-
Terumo Medical CorporationCompletedBenign Prostatic Hyperplasia | Arteriovenous Malformations | Uterine Fibroid | Hypervascular TumorsUnited States
-
Hospital Arnau de VilanovaHospital Universitari de Bellvitge; Hospital Universitari Joan XXIII de Tarragona... and other collaboratorsRecruitingCoronary Artery Disease | Angina, Stable | Angina, Unstable | STEMI | Hematoma | Procedural Pain | Vascular Access Complication | Non STEMI | Artery Occlusion | Procedural Blood Vessel PunctureSpain
-
Maatschap Cardiologie ZwolleTerumo Europe N.V.CompletedComplex Coronary LesionsNetherlands, Belgium, Germany, Switzerland, United Kingdom